Clinical Trials on HIV-1 Infections in Belgium

Total 1635 results

University of Liege

Completed

Effect of Dolutegravir Intensification on HIV-1 Reservoirs (EDIT)

HIV-1-infection

Belgium
Mymetics Corporation
Institut Cochin; San Raffaele University Hospital, Italy; Kinesis Pharma B.V.; ... and other collaborators

Completed

Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects

HIV-1

Belgium
Universitair Ziekenhuis Brussel

Terminated

Body Composition, Bone Health and Hormonal Status in HIV-1-infected Individuals (BONBO)

HIV-1 | Treatment-naïve

Belgium
University Hospital, Ghent
ViiV Healthcare

Recruiting

2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial (2DR)

HIV-1-infection

Belgium
Institute of Tropical Medicine, Belgium
University Hospital, Ghent; Universitair Ziekenhuis Brussel; Agentschap voor... and other collaborators

Completed

Analytical Treatment Interruption in HIV Positive Patients (ISALA)

HIV-1 Infection

Belgium
University Hospital, Ghent
KU Leuven; Universitair Ziekenhuis Brussel; Vrije Universiteit Brussel; Centre... and other collaborators

Not yet recruiting

Immuno-virological Evaluation of Persons Living With HIV (PLWH)

HIV Seropositivity | HIV-1-infection

Belgium
Gilead Sciences

Completed

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

HIV-1 Infection

France, United Kingdom, Spain, Belgium, Ireland
NEAT ID Foundation
ViiV Healthcare

Completed

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N (WISARD)

HIV-1-infection

Spain, Belgium, France, Germany, Italy, United Kingdom
Gilead Sciences

Completed

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

HIV-1 Infection

Spain, United Kingdom, France, Italy, Belgium
Gilead Sciences

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

HIV-1 Infection

Spain, United Kingdom, Italy, France, Belgium
ANRS, Emerging Infectious Diseases
INSERM SC10-US19

Recruiting

Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load (SYNACTHIV)

HIV-1-infection, Subtype b

Belgium, France
International Partnership for Microbicides, Inc.

Completed

A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium

HIV Infections | HIV-1

Belgium
Centre Hospitalier Universitaire Saint Pierre

Completed

Pertussis Immunization During Pregnancy & HIV Infection

Pertussis | Pregnancy | HIV-1-infection | Immunization; Infection

Belgium
Janssen R&D Ireland

Completed

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

HIV-1 Infection

United States, Australia, France, United Kingdom, China, Belgium, Germany, Spain, Argentina, Romania, South Africa, Canada, Denmark, Netherlands, Chile, Puerto Rico, Austria, Russian Federation, Thailand, Sweden, Taiwan
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

HIV-1 Infection

Spain, United Kingdom, Sweden, Germany, United States, France, Belgium, Ireland, Italy, Denmark, Puerto Rico, Canada
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

HIV-1 Infection

United States, United Kingdom, Canada, France, Italy, Puerto Rico, Belgium
Gilead Sciences

Completed

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

HIV-1 Infection

Spain, United States, France, Italy, Germany, Canada, United Kingdom, Belgium, Puerto Rico, Australia
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Spain, United States, Italy, Germany, United Kingdom, France, Australia, Puerto Rico, Canada, Belgium, Dominican Republic
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

HIV-1 Infection

United States, Spain, United Kingdom, Canada, Puerto Rico, France, Belgium, Italy, Germany, Austria
Gilead Sciences

Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

HIV-1 Infection

United States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

France, Spain, Germany, United Kingdom, United States, Puerto Rico, Belgium, Canada, Italy, Dominican Republic
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, France, Germany, United Kingdom, Italy, Canada, Australia, Belgium, Puerto Rico, Dominican Republic
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Canada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
Rigshospitalet, Denmark
Horizon 2020 - European Commission; IrsiCaixa

Not yet recruiting

The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events (MISTRAL)

Inflammation | HIV-1-infection | AIDS

Spain, United Kingdom, Denmark, France, Israel, Germany, Belgium, Croatia, Czechia, Greece, Hungary, Italy, Luxembourg, Poland
GlaxoSmithKline

Terminated

Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

HIV-1

Australia, Belgium, Canada, France, Germany, Greece, Italy, Spain, United Kingdom
Tibotec Pharmaceuticals, Ireland

Completed

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

HIV-1

United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine (MERIT)

HIV-1

United States, Canada, United Kingdom, Netherlands, Argentina, Australia, Belgium, South Africa, Switzerland, Italy, Puerto Rico, Brazil, Mexico, Poland
ViiV Healthcare
Pfizer

Terminated

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 (MODERN)

HIV-1

United States, Netherlands, Spain, Puerto Rico, Canada, Australia, Germany, Sweden, Poland, Portugal, Switzerland, France, Denmark, Italy, Belgium, United Kingdom, Hungary, Austria, Finland
Tibotec Pharmaceuticals, Ireland

Completed

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

HIV-1

United States, Belgium, Germany, Taiwan, Spain, Mexico, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Korea, Republic of, Russian Federation, Puerto Rico, Luxembourg
Centre Hospitalier Universitaire Saint Pierre

Active, not recruiting

Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study) (Papillon)

HIV Infections | HPV - Anogenital Human Papilloma Virus Infection

Belgium
Universitaire Ziekenhuizen KU Leuven

Recruiting

Long Term Follow-up of Patients With Prosthetic Joint Infection of the Hip Treated at University Hospitals Leuven (PROFITH)

Prosthetic Joint Infection | Hip Prosthesis Infection

Belgium
Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
University Hospital, Ghent

Recruiting

HIV Study on MEasuring the Reservoir on Cellular Level to CUre Infection (HIV-Mercuri)

Hiv

Belgium
Hoffmann-La Roche

Terminated

Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)

HIV/HCV Coinfection

Belgium
Cliniques universitaires Saint-Luc- Université...

Completed

Massage Therapy for HIV-positive People : Effects on Anxiety, Depression, Hyperventilation and Quality of Life

HIV-positive Diagnosis

Belgium
University Hospital, Ghent
ViiV Healthcare

Recruiting

Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection (ACS)

HIV | Seroconversion, HIV

Belgium
Cliniques universitaires Saint-Luc- Université...
Université Catholique de Louvain

Completed

Effect of a Specific Aquaporin-1 Inhibitor on Vascular Oxidative Stress in Healthy Volunteers (Bacoxy_II)

Cardiovascular Diseases | Endothelial Dysfunction | Oxidative Stress | Bacopaside II | Bacopa Monnieri | Aquaporin 1 | AQP1

Belgium
Abivax S.A.

Completed

ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment

HIV Infection

Spain, Belgium, France
International AIDS Vaccine Initiative
Children's Hospital of Philadelphia; Nationwide Children's Hospital; Targeted...

Completed

Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine (A001)

HIV Infection

Belgium, Germany, India
Institut Pasteur

Completed

Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine

HIV

Belgium
ViiV Healthcare
GlaxoSmithKline

Completed

HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Belgium, United Kingdom, Italy, Romania, Russian Federation, Switzerland
NEAT ID Foundation
Gilead Sciences

Completed

HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV (HIV CoCo)

COVID-19 | HIV-1-infection

Spain, Germany, Netherlands, United Kingdom, France, Belgium, Italy, Greece
University Hospital, Ghent
Merck Sharp & Dohme LLC

Completed

HIV Sequencing After Treatment Interruption to Identify the Clinically Relevant Anatomical Reservoir (HIV-STAR)

HIV

Belgium
Hasselt University
University Ghent

Completed

HBV/HCV/HIV in Belgian Prisons

HIV Infections | Hepatitis B | Hepatitis C

Belgium
ANRS, Emerging Infectious Diseases

Completed

Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients (ANRS ECHAM)

HIV Infection | Liver Injuries

France, Germany, Belgium
International Partnership for Microbicides, Inc.

Completed

DDI Potential: Dapivirine Vaginal Ring and Miconazole Nitrate

HIV

Belgium
ViiV Healthcare

Terminated

A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

United States, France, Germany, Canada, Italy, Australia, Belgium, Portugal, Puerto Rico, Romania, United Kingdom
GlaxoSmithKline
University Ghent

Completed

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

HIV Infections | Infection, Human Immunodeficiency Virus

Belgium
Theravectys S.A.

Completed

Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).

HIV Infection

France, Belgium

Clinical Trials on HIV-1 Infections in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations